GALMED PHARMACEUTICALS LTD. Available-for-sale Equity Securities, Amortized Cost Basis
GALMED PHARMACEUTICALS LTD. (GLMD) had Available-for-sale Equity Securities, Amortized Cost Basis of $59.97 million as of 2018-12-31, per its 20-F filed 2019-03-13.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis · last filed 2019-03-13
- 2018-12-31: Available-for-sale Equity Securities, Amortized Cost Basis $59.97M.
- 2017-12-31: Available-for-sale Equity Securities, Amortized Cost Basis $5.98M.
- 2016-12-31: Available-for-sale Equity Securities, Amortized Cost Basis $12.44M.
- 2015-12-31: Available-for-sale Equity Securities, Amortized Cost Basis $19.05M; Available-for-sale Equity Securities, Amortized Cost Basis as first filed $23.21M.
| Period end | Available-for-sale Equity Securities, Amortized Cost Basis | Available-for-sale Equity Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2018-12-31 | $59.97M 20-F · filed 2019-03-13 | |
| 2017-12-31 | $5.98M 20-F · filed 2019-03-13 | |
| 2016-12-31 | $12.44M 20-F · filed 2018-03-13 | |
| 2015-12-31 | $19.05M 20-F · filed 2017-03-23 | $23.21M 20-F · filed 2016-03-22 |
| 2014-12-31 | $31.98M 20-F · filed 2016-03-22 | |
| 2013-12-31 | $137.00K 20-F · filed 2015-03-31 |